RT journal article
T1 Identifying patients with prostate cancer at increased risk for haematuria during anticoagulation for venous thromboembolism
A1 Paredes, Diana
A1 Díaz-Pedroche, María del Carmen
A1 Gómez Cuervo, Covadonga
A1 Pérez-Jacoiste, Asunción
A1 Valle, Reina
A1 Blanco-Molina, Ángeles
A1 Blanco-Molina, Ángeles
A1 López Sáez, José Juan Bosco
A1 Meireles, Jose
A1 Sarlon-Bartoli, Gabrielle
A1 Monreal, Manuel
A2 Medicina
K1 Anticoagulation
K1 Bleeding risk
K1 Haematuria
K1 Predictive score
K1 Prostate cancer
K1 Venous thromboembolism
AB Background: Haematuria is a common complication in prostate cancer patients receiving anticoagulation forvenous thromboembolism (VTE). Early identification of at-risk patients might help to reduce its incidence andseverity.Methods: We used data from the RIETE registry to develop a prognostic score for haematuria during the first yearof anticoagulation for VTE. The prognostic score was built using regression coefficients.Results: From March 2001 through March 2021, 1934 patients with prostate cancer and acute VTE were enrolled.Of these, 1034 (53 %) initially presented as pulmonary embolism and 900 (47 %) as isolated deep veinthrombosis (DVT). During anticoagulation (median 181 days; inter-quartile range: 97–354), 99 patients (5.1 %)developed haematuria (fatal 1, major 27, non-major 72). The incidence rate was: 8 events per 100 patient-years(95%CI 6.5–9.7). Median time to haematuria was 53 days (IQR 4–134). On multivariable analysis, recent haematuria,initial presentation as DVT, comorbidity, metastases, haemoglobin levels <11 g/dL, creatinine >1.2mg/dL, and radiotherapy independently predicted the risk for haematuria. C-statistics was 0.71 (95%CI:0.65–0.77). A cut-off of ≥1.5 points classified 312 patients (20 %) at high-risk and had the highest sensitivity (51%; 95%CI: 39–62) and specificity (82 %; 95%CI: 79–83). Our score improved the performance and non-event netreclassification index (NRI) of the RIETE score (c-statistics: 0.61; 95%CI: 0.54–0.68; NRI: 0.09) or VTE-BLEEDscore (c-statistics: 0.64; 95%CI: 0.58–0.71; NRI: 0.76).Conclusions: A prognostic score for haematuria during anticoagulation for VTE performed well in patients withprostate cancer, and improved identification compared to other validated scores
PB Elsevier
SN 0049-3848
YR 2023
FD 2023
LK http://hdl.handle.net/10498/38436
UL http://hdl.handle.net/10498/38436
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 08-nov-2026